nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—EIF4E—forebrain—attention deficit hyperactivity disorder	0.0815	0.119	CbGeAlD
Sirolimus—EIF4E—cardiovascular system—attention deficit hyperactivity disorder	0.0689	0.1	CbGeAlD
Sirolimus—EIF4E—nervous system—attention deficit hyperactivity disorder	0.0442	0.0645	CbGeAlD
Sirolimus—EIF4E—central nervous system—attention deficit hyperactivity disorder	0.0426	0.0621	CbGeAlD
Sirolimus—EIF4E—brain—attention deficit hyperactivity disorder	0.0338	0.0493	CbGeAlD
Sirolimus—FGF2—midbrain—attention deficit hyperactivity disorder	0.0328	0.0478	CbGeAlD
Sirolimus—MTOR—forebrain—attention deficit hyperactivity disorder	0.0315	0.0459	CbGeAlD
Sirolimus—FKBP1A—Alpha-synuclein signaling—STUB1—attention deficit hyperactivity disorder	0.0285	0.0909	CbGpPWpGaD
Sirolimus—FKBP1A—forebrain—attention deficit hyperactivity disorder	0.0284	0.0413	CbGeAlD
Sirolimus—FKBP1A—TGF-beta receptor signaling activates SMADs—STUB1—attention deficit hyperactivity disorder	0.0278	0.0886	CbGpPWpGaD
Sirolimus—MTOR—cardiovascular system—attention deficit hyperactivity disorder	0.0267	0.0388	CbGeAlD
Sirolimus—FGF2—cerebellum—attention deficit hyperactivity disorder	0.0254	0.037	CbGeAlD
Sirolimus—FKBP1A—cardiovascular system—attention deficit hyperactivity disorder	0.024	0.0349	CbGeAlD
Sirolimus—FGF2—brain—attention deficit hyperactivity disorder	0.0206	0.03	CbGeAlD
Sirolimus—FKBP1A—midbrain—attention deficit hyperactivity disorder	0.0187	0.0273	CbGeAlD
Sirolimus—MTOR—nervous system—attention deficit hyperactivity disorder	0.0171	0.0249	CbGeAlD
Sirolimus—MTOR—central nervous system—attention deficit hyperactivity disorder	0.0165	0.024	CbGeAlD
Sirolimus—MTOR—cerebellum—attention deficit hyperactivity disorder	0.0161	0.0235	CbGeAlD
Sirolimus—FKBP1A—nervous system—attention deficit hyperactivity disorder	0.0154	0.0224	CbGeAlD
Sirolimus—FKBP1A—Loss of Function of SMAD2/3 in Cancer—STUB1—attention deficit hyperactivity disorder	0.0149	0.0474	CbGpPWpGaD
Sirolimus—FKBP1A—central nervous system—attention deficit hyperactivity disorder	0.0148	0.0216	CbGeAlD
Sirolimus—FKBP1A—cerebellum—attention deficit hyperactivity disorder	0.0145	0.0211	CbGeAlD
Sirolimus—SLC47A1—nervous system—attention deficit hyperactivity disorder	0.0132	0.0193	CbGeAlD
Sirolimus—MTOR—brain—attention deficit hyperactivity disorder	0.0131	0.0191	CbGeAlD
Sirolimus—SLC47A1—central nervous system—attention deficit hyperactivity disorder	0.0127	0.0186	CbGeAlD
Sirolimus—EIF4E—Insulin Signaling—SNAP23—attention deficit hyperactivity disorder	0.0127	0.0405	CbGpPWpGaD
Sirolimus—SLC47A1—cerebellum—attention deficit hyperactivity disorder	0.0125	0.0181	CbGeAlD
Sirolimus—FKBP1A—Alpha-synuclein signaling—SLC6A3—attention deficit hyperactivity disorder	0.012	0.0384	CbGpPWpGaD
Sirolimus—FKBP1A—brain—attention deficit hyperactivity disorder	0.0118	0.0171	CbGeAlD
Sirolimus—SLC47A1—brain—attention deficit hyperactivity disorder	0.0101	0.0147	CbGeAlD
Sirolimus—SLC47A1—SLC-mediated transmembrane transport—SLC9A9—attention deficit hyperactivity disorder	0.00854	0.0272	CbGpPWpGaD
Sirolimus—FKBP1A—Spinal Cord Injury—RTN4—attention deficit hyperactivity disorder	0.00807	0.0257	CbGpPWpGaD
Sirolimus—ABCB1—forebrain—attention deficit hyperactivity disorder	0.00656	0.00956	CbGeAlD
Sirolimus—SLC47A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—attention deficit hyperactivity disorder	0.00654	0.0208	CbGpPWpGaD
Sirolimus—MTOR—FSH signaling pathway—BDNF—attention deficit hyperactivity disorder	0.00616	0.0196	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB2—STUB1—attention deficit hyperactivity disorder	0.00572	0.0183	CbGpPWpGaD
Sirolimus—ABCB1—cardiovascular system—attention deficit hyperactivity disorder	0.00555	0.00808	CbGeAlD
Sirolimus—FGF2—Mecp2 and Associated Rett Syndrome—BDNF—attention deficit hyperactivity disorder	0.00524	0.0167	CbGpPWpGaD
Sirolimus—MTOR—Insulin Signaling—SNAP23—attention deficit hyperactivity disorder	0.00524	0.0167	CbGpPWpGaD
Sirolimus—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.00503	0.00733	CbGeAlD
Sirolimus—EIF4E—Insulin Signaling—SNAP25—attention deficit hyperactivity disorder	0.00496	0.0158	CbGpPWpGaD
Sirolimus—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.00484	0.00706	CbGeAlD
Sirolimus—FKBP1A—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.0044	0.014	CbGpPWpGaD
Sirolimus—SLC47A1—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.00434	0.0138	CbGpPWpGaD
Sirolimus—ABCB1—midbrain—attention deficit hyperactivity disorder	0.00433	0.00631	CbGeAlD
Sirolimus—MTOR—Signaling by ERBB2—STUB1—attention deficit hyperactivity disorder	0.00425	0.0135	CbGpPWpGaD
Sirolimus—SLC47A1—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.00414	0.0132	CbGpPWpGaD
Sirolimus—EIF4E—BDNF signaling pathway—BDNF—attention deficit hyperactivity disorder	0.00391	0.0125	CbGpPWpGaD
Sirolimus—FGF2—Extracellular matrix organization—MMP16—attention deficit hyperactivity disorder	0.00358	0.0114	CbGpPWpGaD
Sirolimus—ABCB1—nervous system—attention deficit hyperactivity disorder	0.00356	0.00519	CbGeAlD
Sirolimus—ABCB1—central nervous system—attention deficit hyperactivity disorder	0.00343	0.005	CbGeAlD
Sirolimus—FKBP1A—Spinal Cord Injury—BDNF—attention deficit hyperactivity disorder	0.00337	0.0107	CbGpPWpGaD
Sirolimus—ABCB1—cerebellum—attention deficit hyperactivity disorder	0.00335	0.00488	CbGeAlD
Sirolimus—MTOR—HSF1-dependent transactivation—EP300—attention deficit hyperactivity disorder	0.00325	0.0104	CbGpPWpGaD
Sirolimus—SLCO1B1—SLC-mediated transmembrane transport—SLC9A9—attention deficit hyperactivity disorder	0.00305	0.00974	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—RTN4—attention deficit hyperactivity disorder	0.00301	0.00961	CbGpPWpGaD
Sirolimus—SLC47A1—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.00297	0.00947	CbGpPWpGaD
Sirolimus—EIF4E—Validated targets of C-MYC transcriptional activation—EP300—attention deficit hyperactivity disorder	0.00283	0.00903	CbGpPWpGaD
Sirolimus—FKBP1A—TGF-beta Receptor Signaling—EP300—attention deficit hyperactivity disorder	0.00282	0.00898	CbGpPWpGaD
Sirolimus—FKBP1A—Role of Calcineurin-dependent NFAT signaling in lymphocytes—EP300—attention deficit hyperactivity disorder	0.00282	0.00898	CbGpPWpGaD
Sirolimus—ABCB1—brain—attention deficit hyperactivity disorder	0.00272	0.00397	CbGeAlD
Sirolimus—CYP3A4—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.00236	0.00752	CbGpPWpGaD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.00229	0.0073	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—MB21D1—attention deficit hyperactivity disorder	0.00225	0.00718	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—RTN4—attention deficit hyperactivity disorder	0.00224	0.00713	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—STUB1—attention deficit hyperactivity disorder	0.00218	0.00696	CbGpPWpGaD
Sirolimus—CYP3A7—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00216	0.00688	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—MB21D1—attention deficit hyperactivity disorder	0.00215	0.00686	CbGpPWpGaD
Sirolimus—MTOR—Cellular response to heat stress—EP300—attention deficit hyperactivity disorder	0.0021	0.00669	CbGpPWpGaD
Sirolimus—MTOR—Insulin Signaling—SNAP25—attention deficit hyperactivity disorder	0.00204	0.00652	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—STUB1—attention deficit hyperactivity disorder	0.002	0.00638	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—ANK3—attention deficit hyperactivity disorder	0.00198	0.00633	CbGpPWpGaD
Sirolimus—MTOR—IFN-gamma pathway—EP300—attention deficit hyperactivity disorder	0.0019	0.00606	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00181	0.00576	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.00174	0.00553	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—POLR3A—attention deficit hyperactivity disorder	0.00165	0.00527	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—POLR3A—attention deficit hyperactivity disorder	0.00164	0.00524	CbGpPWpGaD
Sirolimus—MTOR—BDNF signaling pathway—BDNF—attention deficit hyperactivity disorder	0.00161	0.00515	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—MB21D1—attention deficit hyperactivity disorder	0.0016	0.00509	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—POLR3A—attention deficit hyperactivity disorder	0.00158	0.00503	CbGpPWpGaD
Sirolimus—CYP3A5—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00156	0.00497	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.00155	0.00495	CbGpPWpGaD
Sirolimus—SLC47A1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.00151	0.00481	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—STUB1—attention deficit hyperactivity disorder	0.00148	0.00473	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.00148	0.00472	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—STUB1—attention deficit hyperactivity disorder	0.00148	0.00471	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00141	0.0045	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—CACNB2—attention deficit hyperactivity disorder	0.0014	0.00446	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00133	0.00423	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—CACNA1C—attention deficit hyperactivity disorder	0.00128	0.00408	CbGpPWpGaD
Sirolimus—FGF2—Immune System—MB21D1—attention deficit hyperactivity disorder	0.00125	0.00399	CbGpPWpGaD
Sirolimus—FGF2—Immune System—STUB1—attention deficit hyperactivity disorder	0.00121	0.00387	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00121	0.00386	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00119	0.00379	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—POLR3A—attention deficit hyperactivity disorder	0.00117	0.00373	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00116	0.00371	CbGpPWpGaD
Sirolimus—CYP3A7—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00115	0.00368	CbGpPWpGaD
Sirolimus—CYP3A7—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00115	0.00365	CbGpPWpGaD
Sirolimus—CYP3A7—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00114	0.00363	CbGpPWpGaD
Sirolimus—FGF2—Disease—STUB1—attention deficit hyperactivity disorder	0.00112	0.00357	CbGpPWpGaD
Sirolimus—SLCO1B1—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.00106	0.00339	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00103	0.0033	CbGpPWpGaD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.00103	0.00327	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.001	0.0032	CbGpPWpGaD
Sirolimus—MTOR—Immune System—MB21D1—attention deficit hyperactivity disorder	0.000929	0.00296	CbGpPWpGaD
Sirolimus—FGF2—Immune System—POLR3A—attention deficit hyperactivity disorder	0.000919	0.00293	CbGpPWpGaD
Sirolimus—MTOR—Immune System—STUB1—attention deficit hyperactivity disorder	0.0009	0.00287	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000889	0.00283	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000871	0.00278	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000854	0.00272	CbGpPWpGaD
Sirolimus—CYP3A5—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000834	0.00266	CbGpPWpGaD
Sirolimus—MTOR—Disease—STUB1—attention deficit hyperactivity disorder	0.000831	0.00265	CbGpPWpGaD
Sirolimus—CYP3A5—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000828	0.00264	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000823	0.00262	CbGpPWpGaD
Sirolimus—CYP3A5—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000823	0.00262	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000784	0.0025	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.000777	0.00248	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.000777	0.00248	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000745	0.00238	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.000741	0.00236	CbGpPWpGaD
Sirolimus—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000725	0.00231	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000719	0.00229	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—SNAP25—attention deficit hyperactivity disorder	0.000701	0.00223	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.000696	0.00222	CbGpPWpGaD
Sirolimus—MTOR—Immune System—POLR3A—attention deficit hyperactivity disorder	0.000682	0.00217	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000674	0.00215	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000669	0.00213	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00066	0.0021	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000648	0.00207	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000647	0.00206	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000637	0.00203	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000629	0.002	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000604	0.00192	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000586	0.00187	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000582	0.00186	CbGpPWpGaD
Sirolimus—ABCB1—HIF-1-alpha transcription factor network—EP300—attention deficit hyperactivity disorder	0.000581	0.00185	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.000555	0.00177	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.00054	0.00172	CbGpPWpGaD
Sirolimus—FGF2—Disease—SNAP25—attention deficit hyperactivity disorder	0.000531	0.00169	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000528	0.00168	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000514	0.00164	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.0005	0.00159	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000491	0.00156	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00049	0.00156	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00048	0.00153	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000475	0.00151	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000472	0.0015	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000467	0.00149	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000461	0.00147	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000458	0.00146	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—EP300—attention deficit hyperactivity disorder	0.000445	0.00142	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.00043	0.00137	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.00041	0.00131	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.0004	0.00128	CbGpPWpGaD
Sirolimus—MTOR—Disease—SNAP25—attention deficit hyperactivity disorder	0.000394	0.00126	CbGpPWpGaD
Sirolimus—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000388	0.00124	CbGpPWpGaD
Sirolimus—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000385	0.00123	CbGpPWpGaD
Sirolimus—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000382	0.00122	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000372	0.00119	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000363	0.00116	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.00036	0.00115	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000355	0.00113	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000355	0.00113	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000354	0.00113	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.00035	0.00111	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000349	0.00111	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000341	0.00109	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.00034	0.00108	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—EP300—attention deficit hyperactivity disorder	0.000336	0.00107	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000326	0.00104	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000326	0.00104	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000326	0.00104	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000325	0.00104	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000321	0.00102	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—DPYD—attention deficit hyperactivity disorder	0.00032	0.00102	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000301	0.000959	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000298	0.00095	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000297	0.000946	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000284	0.000905	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000276	0.00088	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.00027	0.000862	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.00027	0.000861	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000267	0.000852	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000263	0.000837	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.00026	0.00083	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000259	0.000827	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000257	0.000821	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.000248	0.000791	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000248	0.00079	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000242	0.00077	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000238	0.000759	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000235	0.000751	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000235	0.000751	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000232	0.000739	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000228	0.000727	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—EP300—attention deficit hyperactivity disorder	0.000228	0.000726	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000217	0.000693	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000215	0.000687	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—COMT—attention deficit hyperactivity disorder	0.000215	0.000686	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000214	0.000681	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000207	0.00066	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—COMT—attention deficit hyperactivity disorder	0.000197	0.000629	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000196	0.000625	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000188	0.0006	CbGpPWpGaD
Sirolimus—FGF2—Immune System—EP300—attention deficit hyperactivity disorder	0.000187	0.000596	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000179	0.000571	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000178	0.000567	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000178	0.000567	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000175	0.000557	CbGpPWpGaD
Sirolimus—FGF2—Disease—EP300—attention deficit hyperactivity disorder	0.000173	0.00055	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000169	0.00054	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000163	0.000518	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000159	0.000508	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000159	0.000506	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—COMT—attention deficit hyperactivity disorder	0.000143	0.000455	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000142	0.000453	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000142	0.000452	CbGpPWpGaD
Sirolimus—MTOR—Immune System—EP300—attention deficit hyperactivity disorder	0.000139	0.000442	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000135	0.000431	CbGpPWpGaD
Sirolimus—MTOR—Disease—EP300—attention deficit hyperactivity disorder	0.000128	0.000408	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000121	0.000385	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000109	0.000349	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000109	0.000349	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000108	0.000343	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—COMT—attention deficit hyperactivity disorder	0.000108	0.000343	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000107	0.000341	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.0001	0.000319	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—EP300—attention deficit hyperactivity disorder	9.22e-05	0.000294	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EP300—attention deficit hyperactivity disorder	8.97e-05	0.000286	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	8.75e-05	0.000279	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—EP300—attention deficit hyperactivity disorder	8.46e-05	0.00027	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	8.33e-05	0.000266	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	6.63e-05	0.000211	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	6.59e-05	0.00021	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—EP300—attention deficit hyperactivity disorder	6.12e-05	0.000195	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—EP300—attention deficit hyperactivity disorder	4.62e-05	0.000147	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	2.84e-05	9.07e-05	CbGpPWpGaD
